Europe opens gates to CAR-T
First two modified T-Cell cancer therapies approved in the EU, but prices may be prohibitive for public health systems
The first two chimeric antigen receptor T-cell (CAR-T) therapies have been approved for use in the EU. However, there are already concerns that they will not be available for patients in some countries because of the cost.
Both drugs were approved in the US in 2017 – Novartis’ Kymriah (tisagenlecleucel) in August, and Kite–Gilead’s Yescarta (axicabtagene ciloleucel) in October.